11 results on '"Shamika Ketkar"'
Search Results
2. Leukocyte-dependent effects of platelet-rich plasma on cartilage loss and thermal hyperalgesia in a mouse model of post-traumatic osteoarthritis
- Author
-
Matthew W. Grol, Prathap Jayaram, Brian Dawson, Brendan Lee, C. Liu, Shiv J. Patel, and Shamika Ketkar
- Subjects
Cartilage, Articular ,0301 basic medicine ,Biomedical Engineering ,Osteoarthritis ,Pharmacology ,Menisci, Tibial ,Injections, Intra-Articular ,Pathogenesis ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Synovitis ,Leukocytes ,Animals ,Medicine ,Orthopedics and Sports Medicine ,030203 arthritis & rheumatology ,Platelet-Rich Plasma ,business.industry ,Cartilage ,Chronic pain ,X-Ray Microtomography ,Osteoarthritis, Knee ,medicine.disease ,Tibial Meniscus Injuries ,nervous system diseases ,Disease Models, Animal ,030104 developmental biology ,medicine.anatomical_structure ,Nociception ,Hyperalgesia ,Platelet-rich plasma ,Disease Progression ,medicine.symptom ,business - Abstract
Summary Objective Platelet-rich plasma (PRP) is an emerging therapeutic strategy for treatment of osteoarthritis (OA); however, there is a lack of preclinical and clinical evidence for its efficacy and its mechanism of action is unclear. In the current study, we utilized leukocyte poor-PRP (LP-PRP) and leukocyte rich-PRP (LR-PRP) to mimic clinical point of care formulations and assessed their potential to alter disease progression in a mouse model of post-traumatic OA. Method Three-month-old wild-type male FVB/N mice received destabilization of the medial meniscus (DMM) surgery to induce OA. To assess the efficacy of LP-PRP and LR-PRP, mice were given intraarticular injections at 2-, 7- and 28-days post-surgery. Mice were then assessed at 5-, 9-, and 13-weeks post-surgery for changes in chronic pain using the hot plate nociceptive assay. At 14-weeks, OA pathogenesis was evaluated using histology and phase-contrast μCT. Results Treatment with LP-PRP and to a lesser extent LR-PRP preserved cartilage volume and surface area compared to phosphate-buffered saline (PBS) as measured by phase-contrast μCT. However, both treatments had higher Osteoarthritis Research Society International (OARSI) and synovitis scores compared to sham, and neither substantially improved scores compared to PBS controls. With respect to thermal hyperalgesia, PBS-treated mice displayed reduced latency to response compared to sham, and LR-PRP but not LP-PRP improved latency to response at 5-, 9- and 13-weeks post-surgery compared to PBS. Conclusion The results of this study suggest that effects of PRP therapy on OA progression and disease-induced hyperalgesia may be leukocyte-dependent. And while LP-PRP and to a lesser extent LR-PRP protect from volume and surface loss, significant pathology is still seen within OA joints. Future work is needed to understand how the different components of PRP effect OA pathogenesis and pain, and how these could be modified to achieve greater therapeutic efficacy.
- Published
- 2020
3. Transcriptome-directed analysis for Mendelian disease diagnosis overcomes limitations of conventional genomic testing
- Author
-
Paolo Moretti, Shan Chen, Gladys Zapata, Michaela F. Müller, Carlos A. Bacino, William J. Craigen, Julien Gagneur, Hsiao-Tuan Chao, Shamika Ketkar, Hongzheng Dai, Vicente A. Yépez, Neil A. Hanchard, David R. Murdock, Lindsay C. Burrage, Brendan Lee, Jill A. Rosenfeld, Pengfei Liu, and Mahim Jain
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Adolescent ,Microarray ,Bioinformatics ,DNA sequencing ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Molecular genetics ,Intellectual disability ,medicine ,Humans ,RNA-Seq ,Child ,Exome ,Skin ,business.industry ,Genetic Diseases, Inborn ,General Medicine ,Fibroblasts ,medicine.disease ,030104 developmental biology ,Child, Preschool ,030220 oncology & carcinogenesis ,Cohort ,Mendelian inheritance ,symbols ,Female ,Personalized medicine ,Clinical Medicine ,business - Abstract
BACKGROUND: Transcriptome sequencing (RNA-seq) improves diagnostic rates in individuals with suspected Mendelian conditions to varying degrees, primarily by directing the prioritization of candidate DNA variants identified on exome or genome sequencing (ES/GS). Here we implemented an RNA-seq–guided method to diagnose individuals across a wide range of ages and clinical phenotypes. METHODS: One hundred fifteen undiagnosed adult and pediatric patients with diverse phenotypes and 67 family members (182 total individuals) underwent RNA-seq from whole blood and skin fibroblasts at the Baylor College of Medicine (BCM) Undiagnosed Diseases Network clinical site from 2014 to 2020. We implemented a workflow to detect outliers in gene expression and splicing for cases that remained undiagnosed despite standard genomic and transcriptomic analysis. RESULTS: The transcriptome-directed approach resulted in a diagnostic rate of 12% across the entire cohort, or 17% after excluding cases solved on ES/GS alone. Newly diagnosed conditions included Koolen–de Vries syndrome (KANSL1), Renpenning syndrome (PQBP1), TBCK-associated encephalopathy, NSD2- and CLTC-related intellectual disability, and others, all with negative conventional genomic testing, including ES and chromosomal microarray (CMA). Skin fibroblasts exhibited higher and more consistent expression of clinically relevant genes than whole blood. In solved cases with RNA-seq from both tissues, the causative defect was missed in blood in half the cases but none from fibroblasts. CONCLUSIONS: For our cohort of undiagnosed individuals with suspected Mendelian conditions, transcriptome-directed genomic analysis facilitated diagnoses, primarily through the identification of variants missed on ES and CMA. TRIAL REGISTRATION: Not applicable. FUNDING: NIH Common Fund, BCM Intellectual and Developmental Disabilities Research Center, Eunice Kennedy Shriver National Institute of Child Health & Human Development.
- Published
- 2021
4. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma
- Author
-
Manik Kuvalekar, Adrian P. Gee, Juan F. Vera, Meng-Fen Wu, Rammurti T. Kamble, Tao Wang, Mrinalini Bilgi, Carlos A. Ramos, Ayumi Watanabe, Premal Lulla, Mira Jeong, Shamika Ketkar, Matthew French-Kim, Spyridoula Vasileiou, Betty Chung, George Carrum, Bambi Grilley, Ann M. Leen, Malcolm K. Brenner, Shivani Mukhi, Linghua Wang, Helen E. Heslop, Yumei Li, and Ifigeneia Tzannou
- Subjects
Oncology ,medicine.medical_specialty ,PRAME ,business.industry ,T cell ,Cell- and Tissue-Based Therapy ,Receptors, Antigen, T-Cell ,General Medicine ,medicine.disease ,Prior Therapy ,medicine.anatomical_structure ,Refractory ,Antigen ,Antigens, Neoplasm ,Internal medicine ,Concomitant ,medicine ,Humans ,Neoplasm Recurrence, Local ,Multiple Myeloma ,business ,Multiple myeloma ,Ex vivo - Abstract
Multiple myeloma (MM) is an almost always incurable malignancy of plasma cells. Despite the advent of new therapies, most patients eventually relapse or become treatment-refractory. Consequently, therapies with nonoverlapping mechanisms of action that are nontoxic and provide long-term benefit to patients with MM are greatly needed. To this end, we clinically tested an autologous multitumor-associated antigen (mTAA)-specific T cell product for the treatment of patients with high-risk, relapsed or refractory MM. In this study, we expanded polyclonal T cells from 23 patients with MM. T cells whose native T cell receptors were reactive toward five myeloma-expressed target TAAs (PRAME, SSX2, MAGEA4, Survivin, and NY-ESO-1) were enriched ex vivo. To date, we have administered escalating doses of these nonengineered mTAA-specific T cells (0.5 × 107 to 2 × 107 cells/m2) to 21 patients with MM, 9 of whom were at high risk of relapse after a median of 3 lines of prior therapy and 12 with active, relapsed or refractory disease after a median of 3.5 prior lines. The cells were well tolerated, with only two transient, grade III infusion-related adverse events. Furthermore, patients with active relapsed or refractory myeloma enjoyed a longer than expected progression-free survival and responders included three patients who achieved objective responses concomitant with detection of functional TAA-reactive T cell clonotypes derived from the infused mTAA product.
- Published
- 2020
5. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
- Author
-
Eric J. Duncavage, Michelle O'Laughlin, Jeffery M. Klco, Bradley A. Ozenberger, Allegra A. Petti, Dong Shen, Catrina Fronick, Elaine R. Mardis, Richard K. Wilson, Lukas D. Wartman, Matthew J. Walter, Robert S. Fulton, Obi L. Griffith, Peter Westervelt, David H. Spencer, Sharon Heath, Shamika Ketkar-Kulkarni, Malachi Griffith, Timothy A. Graubert, Shashikant Kulkarni, Christopher A. Miller, Tamara Lamprecht, Jerald P. Radich, Ryan Demeter, Gue Su Chang, John F. DiPersio, Nicole M. Helton, Jack Baty, Matthew J. Christopher, Jacqueline E. Payton, Vincent Magrini, Jasreet Hundal, Timothy J. Ley, John S. Welch, Daniel C. Link, and David E. Larson
- Subjects
Adult ,Male ,medicine.medical_specialty ,Myeloid ,medicine.medical_treatment ,Gastroenterology ,Disease-Free Survival ,Bone Marrow ,Recurrence ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Outcome Assessment, Health Care ,medicine ,Idarubicin ,Humans ,RNA, Messenger ,Exome sequencing ,Chemotherapy ,Polymorphism, Genetic ,business.industry ,Genome, Human ,Sequence Analysis, RNA ,Daunorubicin ,Cytarabine ,Induction chemotherapy ,General Medicine ,Induction Chemotherapy ,Middle Aged ,medicine.disease ,Prognosis ,Chemotherapy regimen ,Surgery ,Leukemia ,Leukemia, Myeloid, Acute ,MicroRNAs ,medicine.anatomical_structure ,Mutation ,Female ,business ,medicine.drug - Abstract
Importance Tests that predict outcomes for patients with acute myeloid leukemia (AML) are imprecise, especially for those with intermediate risk AML. Objectives To determine whether genomic approaches can provide novel prognostic information for adult patients with de novo AML. Design, Setting, and Participants Whole-genome or exome sequencing was performed on samples obtained at disease presentation from 71 patients with AML (mean age, 50.8 years) treated with standard induction chemotherapy at a single site starting in March 2002, with follow-up through January 2015. In addition, deep digital sequencing was performed on paired diagnosis and remission samples from 50 patients (including 32 with intermediate-risk AML), approximately 30 days after successful induction therapy. Twenty-five of the 50 were from the cohort of 71 patients, and 25 were new, additional cases. Exposures Whole-genome or exome sequencing and targeted deep sequencing. Risk of identification based on genetic data. Main Outcomes and Measures Mutation patterns (including clearance of leukemia-associated variants after chemotherapy) and their association with event-free survival and overall survival. Results Analysis of comprehensive genomic data from the 71 patients did not improve outcome assessment over current standard-of-care metrics. In an analysis of 50 patients with both presentation and documented remission samples, 24 (48%) had persistent leukemia-associated mutations in at least 5% of bone marrow cells at remission. The 24 with persistent mutations had significantly reduced event-free survival vs the 26 who cleared all mutations (median [95% CI]: 6.0 months [95% CI, 3.7-9.6] for persistent mutations vs 17.9 months [95% CI, 11.3-40.4] for cleared mutations, log-rank P P P = .003; HR, 2.86 [95% CI, 1.39-5.88], P = .004). Among the 32 patients with intermediate cytogenetic risk, the 14 patients with persistent mutations had reduced event-free survival compared with the 18 patients who cleared all mutations (median [95% CI]: 8.8 months [95% CI, 3.7-14.6] for persistent mutations vs 25.6 months [95% CI, 11.4-not estimable] for cleared mutations, log-rank P = .003; HR, 3.32 [95% CI, 1.44-7.67], P = .005) and reduced overall survival (median [95% CI]: 19.3 months [95% CI, 7.5-42.3] for persistent mutations vs 46.8 months [95% CI, 22.6-not estimable] for cleared mutations, log-rank P = .02; HR, 2.88 [95% CI, 1.11-7.45], P = .03). Conclusions and Relevance The detection of persistent leukemia-associated mutations in at least 5% of bone marrow cells in day 30 remission samples was associated with a significantly increased risk of relapse, and reduced overall survival. These data suggest that this genomic approach may improve risk stratification for patients with AML.
- Published
- 2015
6. Abstract PR11: Genomic approaches for risk assessment in acute myeloid leukemia
- Author
-
Jasreet Hundal, John S. Welch, Daniel C. Link, Malachi Griffith, Jerald P. Radich, Michelle O'Laughlin, Jeffery M. Klco, Shashikant Kulkarni, Tamara Lamprecht, Catrina Fronick, Allegra A. Petti, Timothy A. Graubert, Ryan Demeter, Lukas D. Wartman, Bradley A. Ozenberger, Vincent Magrini, Matthew J. Christopher, Jacqueline E. Payton, Peter Westervelt, Sharon Heath, Matthew Walker, Dong Shen, Elaine R. Mardis, Richard K. Wilson, Jack Baty, Obi L. Griffith, Christopher A. Miller, Gue Su Chang, David E. Larson, David H. Spencer, Shamika Ketkar-Kulkarni, John F. DiPersio, and Robert S. Fulton
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Myeloid leukemia ,Induction chemotherapy ,Adult Acute Myeloid Leukemia ,medicine.disease ,Haematopoiesis ,Leukemia ,medicine.anatomical_structure ,Internal medicine ,Immunology ,medicine ,Bone marrow ,business ,Exome sequencing - Abstract
Acute myeloid leukemia is heterogeneous with respect to clinical outcome and molecular pathogenesis. Approximately 20% of AML cases are refractory to induction chemotherapy, and about 50% of patients ultimately relapse within a time interval that ranges from months to years. At the molecular level, diverse chromosomal abnormalities and genetic mutations have been observed across patients1. Although several clinical factors (age, white blood cell count), cytogenetic aberrations (t[15;17] translocation, loss of chromosome 5) 2-4, and genetic mutations (DNMT3A, FLT3) have been associated with differences in survival 5,6, these factors are of limited prognostic utility. Moreover, few studies have integrated sequence data with clinical and cytogentic factors to build predictive models of patient outcome. Here, we sought to identify genomic predictors of refractory disease or early relapse. We used whole genome and exome sequencing to analyze the genomes of 71 adult de novo AML patients treated with anthracycline and cytarabine-based induction chemotherapy. Of these, 34 had refractory disease or relapsed within 6 months, 12 relapsed in 6-12 months, and 25 had a long first remission (>12 months). We also developed an enhanced exome sequencing (EES) approach to identify and follow leukemia-associated variants over time. In 12 additional patients that achieved morphologic remission after induction chemotherapy, we used EES to identify and track variants at time of diagnosis, time of morphologic remission (roughly 30 days later), and a final time point corresponding to eventual relapse (n=8) or extended remission (n=4). No novel coding or non-coding variants present at the time of diagnosis were found to be predictive of refractory disease or early relapse. Using EES, however, we were able to detect leukemia-associated variants in the initial remission bone marrow in all eight patients who eventually relapsed. One persistent leukemia-associated variant was also detected in one patient still in remission, but all other variants in that patient were eliminated. We also detected 64 somatic variants that became enriched following chemotherapy, but were not detected in the original leukemic cells. These may represent relapse-specific variants or oligoclonal hematopoiesis after bone marrow recovery. Overall, our data suggest that the persistence of leukemia-associated variants after bone marrow recovery from cytotoxic therapy is strongly correlated with relapse, and may be used to complement more traditional, morphologic measures of leukemic cell clearance. 1. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England Journal of Medicine 2013;368:2059-74. 2. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36. 3. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-65. 4. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. The New England Journal of Medicine 2008;358:1909-18. 5. Kihara R, Nagata Y, Kiyoi H, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28:1586-95. 6. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. The New England Journal of Medicine 2010;363:2424-33. Citation Format: Jeffery M. Klco, Christopher A. Miller, Malachi Griffith, Allegra Petti, David H. Spencer, Shamika Ketkar-Kulkarni, Lukas D. Wartman, Matthew Christopher, Tamara L. Lamprecht, Jacqueline E. Payton, Jack Baty, Sharon E. Heath, Obi L. Griffith, Dong Shen, Jasreet Hundal, Gue Su Chang, Robert S. Fulton, Michelle O'laughlin, Catrina Fronick, Vincent Magrini, Ryan Demeter, David E. Larson, Shashikant Kulkarni, Bradley A. Ozenberger, John S. Welch, Matthew J. Walker, Timothy A. Graubert, Peter Westervelt, Jerald P. Radich, Daniel C. Link, Elaine R. Mardis, John F. DiPersio, Richard K. Wilson. Genomic approaches for risk assessment in acute myeloid leukemia. [abstract]. In: Proceedings of the AACR Special Conference on Translation of the Cancer Genome; Feb 7-9, 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 1):Abstract nr PR11.
- Published
- 2015
7. Abstract PR03: Genomic approaches for risk assessment in acute myeloid leukemia
- Author
-
Vincent Magrini, Timothy A. Graubert, Malachi Griffith, Jack Baty, Sharon Heath, Richard K. Wilson, Obi L. Griffith, Catrina Fronick, Jerald P. Radich, Christopher A. Miller, Jeffery M. Klco, John F. DiPersio, Michelle O'Laughlin, Jacqueline E. Payton, John S. Welch, David H. Spencer, Daniel C. Link, Shamika Ketkar-Kulkarni, Bradley A. Ozenberger, Gue Su Chang, Lukas D. Wartman, Jasreet Hundal, Robert S. Fulton, Dong Shen, Shashikant Kulkarni, Allegra A. Petti, David E. Larson, Elaine R. Mardis, Matthew J. Christopher, Tamara Lamprecht, Ryan Demeter, Peter Westervelt, and Matthew Walker
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Myeloid leukemia ,Induction chemotherapy ,Adult Acute Myeloid Leukemia ,medicine.disease ,Leukemia ,Haematopoiesis ,medicine.anatomical_structure ,Internal medicine ,medicine ,Bone marrow ,business ,Exome sequencing - Abstract
Acute myeloid leukemia is heterogeneous with respect to clinical outcome and molecular pathogenesis. Approximately 20% of AML cases are refractory to induction chemotherapy, and about 50% of patients ultimately relapse within a time interval that ranges from months to years. At the molecular level, diverse chromosomal abnormalities and genetic mutations have been observed across patients1. Although several clinical factors (age, white blood cell count), cytogenetic aberrations (t[15;17] translocation, loss of chromosome 5) 2-4, and genetic mutations (DNMT3A, FLT3) have been associated with differences in survival 5,6, these factors are of limited prognostic utility. Moreover, few studies have integrated sequence data with clinical and cytogentic factors to build predictive models of patient outcome. Here, we sought to identify genomic predictors of refractory disease or early relapse. We used whole genome and exome sequencing to analyze the genomes of 71 adult de novo AML patients treated with anthracycline and cytarabine-based induction chemotherapy. Of these, 34 had refractory disease or relapsed within 6 months, 12 relapsed in 6-12 months, and 25 had a long first remission (>12 months). We also developed an enhanced exome sequencing (EES) approach to identify and follow leukemia-associated variants over time. In 12 additional patients that achieved morphologic remission after induction chemotherapy, we used EES to identify and track variants at time of diagnosis, time of morphologic remission (roughly 30 days later), and a final time point corresponding to eventual relapse (n=8) or extended remission (n=4). No novel coding or non-coding variants present at the time of diagnosis were found to be predictive of refractory disease or early relapse. Using EES, however, we were able to detect leukemia-associated variants in the initial remission bone marrow in all eight patients who eventually relapsed. One persistent leukemia-associated variant was also detected in one patient still in remission, but all other variants in that patient were eliminated. We also detected 64 somatic variants that became enriched following chemotherapy, but were not detected in the original leukemic cells. These may represent relapse-specific variants or oligoclonal hematopoiesis after bone marrow recovery. Overall, our data suggest that the persistence of leukemia-associated variants after bone marrow recovery from cytotoxic therapy is strongly correlated with relapse, and may be used to complement more traditional, morphologic measures of leukemic cell clearance. 1. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England Journal of Medicine 2013;368:2059-74. 2. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36. 3. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-65. 4. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. The New England Journal of Medicine 2008;358:1909-18. 5. Kihara R, Nagata Y, Kiyoi H, et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014;28:1586-95. 6. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. The New England Journal of Medicine 2010;363:2424-33. This abstract is also presented as a poster at the Translation of the Cancer Genome conference. Citation Format: Jeffery M. Klco, Christopher A. Miller, Malachi Griffith, Allegra Petti, David H. Spencer, Shamika Ketkar-Kulkarni, Lukas D. Wartman, Matthew Christopher, Tamara L. Lamprecht, Jacqueline E. Payton, Jack Baty, Sharon E. Heath, Obi L. Griffith, Dong Shen, Jasreet Hundal, Gue Su Chang, Robert S. Fulton, Michelle O'laughlin, Catrina Fronick, Vincent Magrini, Ryan Demeter, David E. Larson, Shashikant Kulkarni, Bradley A. Ozenberger, John S. Welch, Matthew J. Walker, Timothy A. Graubert, Peter Westervelt, Jerald P. Radich, Daniel C. Link, Elaine R. Mardis, John F. DiPersio, Richard K. Wilson. Genomic approaches for risk assessment in acute myeloid leukemia. [abstract]. In: Proceedings of the AACR Special Conference on Computational and Systems Biology of Cancer; Feb 8-11 2015; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(22 Suppl 2):Abstract nr PR03.
- Published
- 2015
8. Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status
- Author
-
Jose M. Ordovas, Ingrid B. Borecki, Mary F. Feitosa, Donna K. Arnett, Shamika Ketkar, Ping An, Robert J. Straka, and Paul N. Hopkins
- Subjects
Adult ,Male ,medicine.medical_specialty ,Apolipoproteins A ,Article ,Apolipoproteins E ,Fenofibrate ,Internal medicine ,medicine ,Humans ,Serum triglycerides ,Gene ,Triglycerides ,Aged ,Dyslipidemias ,Metabolic Syndrome ,Atherogenic dyslipidemia ,business.industry ,Cholesterol, HDL ,Lipid metabolism ,Cholesterol, LDL ,Middle Aged ,medicine.disease ,Lipid Metabolism ,Endocrinology ,Apolipoprotein A-V ,lipids (amino acids, peptides, and proteins) ,Female ,Metabolic syndrome ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Fenofibrate therapy reduces serum triglycerides (TG) and increases high-density lipoprotein-cholesterol (HDL-C) and thus addresses the atherogenic dyslipidemia associated with metabolic syndrome (MetS). Our hypothesis is that genetic factors contribute to the variability of lipid response to fenofibrate differently in subjects with MetS and without MetS.We investigated the association in 25 candidate genes with lipid responses to a 3-weeks trial on fenofibrate in subjects with and without MetS. We employed growth curve mixed models to generate the response phenotypes to fenofibrate in TG, HDL-C, and low-density lipoprotein-cholesterol (LDL-C) and examined the genetic associations accounting for family dependencies.After correcting for multiple testing (p0.05) and accounting for significant differences in the association effect sizes between subjects with and without MetS (p0.05), variants of APOA5 (rs662799) and APOE (rs429358) were associated with HDL-C and LDL-C responses in MetS subjects, while APOA4 (rs675) was associated with TG response in non-MetS subjects. There was also suggestive evidence that MetS may interact with APOA4 (p=0.017), APOA5 (p=0.06), and APOE (p=0.09) to the variation to lipid responses.Genetic effects that contributed to the variability of lipid responses to fenofibrate may differ in subjects with and without MetS. This research may provide guidance for more personalized and effective therapies.
- Published
- 2010
9. Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study
- Author
-
Ping An, Mary F. Feitosa, Ingrid B. Borecki, Shamika Ketkar, Michael A. Province, Shiow Lin, and Avril Adelman
- Subjects
Oncology ,medicine.medical_specialty ,endocrine system ,endocrine system diseases ,Offspring ,Type 2 diabetes ,Bioinformatics ,Logistic regression ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,0302 clinical medicine ,Framingham Heart Study ,Polymorphism (computer science) ,Internal medicine ,medicine ,SNP ,030304 developmental biology ,0303 health sciences ,business.industry ,nutritional and metabolic diseases ,General Medicine ,medicine.disease ,Proceedings ,030220 oncology & carcinogenesis ,Cohort ,business ,TCF7L2 - Abstract
Fifteen known type 2 diabetes (T2D) gene variants were assessed for their associations with T2D status in 228 T2D families from the Framingham Heart Study (FHS) Original, Offspring, and Children Cohorts. Bayesian approach was used to test single-single-nucleotide polymorphism (SNP) association followed by logistic regression. Bayesian and logic regression approaches were used to test multiple SNP association searching for the best combinations of variants followed by logistic regression reconfirmation. The significant variants for T2D risk were also tested for their main and interacting effects on triglyceride (TG)/high-density lipoprotein (HDL) ratio change derived from four point measures across time. This slope phenotype was made available using mixed model growth curve approach from 155 T2D families in the FHS Offspring Cohort. Results CDKN2B rs10811661 (p = 0.042), TCF7L2 rs4506565 (p = 0.004), and JAZF1 rs864745 (p = 0.04) were individually associated with risk of T2D (OR = 1.0-2.0; effect size
- Published
- 2009
10. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium
- Author
-
Eliot Riboli, Howard M. Cann, Sholom Wacholder, Malcolm C. Pike, Kim Overvad, Philip Bretsky, Richard B. Hayes, V. Wendy Setiawan, Maria J. Sánchez, Laurence N. Kolonel, David J. Hunter, Alison M. Dunning, Christopher A. Haiman, Noël P. Burtt, Ruth C. Travis, Matthew L. Freedman, Meir J. Stampfer, Christine D. Berg, David Altshuler, Brian E. Henderson, Göran Hallmans, Domenico Palli, Federico Canzian, Jarmo Virtamo, Heather Spencer Feigelson, Bas Bueno-de-Mesquita, Shamika Ketkar, Paul D. Pharaoh, Antonia Trichopoulou, Stephen J. Chanock, Yen-Ching Chen, Carmen Rodriguez, Michael J. Thun, Gerald L. Andriole, J. Michael Gaziano, Daniel O. Stram, Loic LeMarchand, Stephanie J. Weinstein, Rudolf Kaaks, Gilles Thomas, Demetrius Albanes, Peter Kraft, Timothy J. Key, Jing Ma, Joel N. Hirschhorn, Heiner Boeing, and Edward Giovannucci
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Genotype ,Epidemiology ,Mammary gland ,Breast Neoplasms ,Polymorphism, Single Nucleotide ,Risk Assessment ,Cohort Studies ,Prostate cancer ,Breast cancer ,Internal medicine ,Epidemiology of cancer ,medicine ,Estrogen Receptor beta ,Humans ,Genetic Predisposition to Disease ,Risk factor ,Estrogen receptor beta ,Aged ,Neoplasm Staging ,Gynecology ,business.industry ,Cancer ,Genetic Variation ,Prostatic Neoplasms ,Exons ,Sequence Analysis, DNA ,medicine.disease ,Prognosis ,medicine.anatomical_structure ,Haplotypes ,Case-Control Studies ,Cohort ,Female ,business - Abstract
Background: Estrogen receptor β (ESR2) may play a role in modulating prostate carcinogenesis through the regulation of genes related to cell proliferation and apoptosis. Methods: We conducted nested case-control studies in the Breast and Prostate Cancer Cohort Consortium (BPC3) that pooled 8,323 prostate cancer cases and 9,412 controls from seven cohorts. Whites were the predominant ethnic group. We characterized genetic variation in ESR2 by resequencing exons in 190 breast and prostate cancer cases and genotyping a dense set of single nucleotide polymorphisms (SNP) spanning the locus in a multiethnic panel of 349 cancer-free subjects. We selected four haplotype-tagging SNPs (htSNP) to capture common ESR2 variation in Whites; these htSNPs were then genotyped in all cohorts. Conditional logistic regression models were used to assess the association between sequence variants of ESR2 and the risk of prostate cancer. We also investigated the effect modification by age, body mass index, and family history, as well as the association between sequence variants of ESR2 and advanced-stage (≥T3b, N1, or M1) and high-grade (Gleason sum ≥8) prostate cancer, respectively. Results: The four tag SNPs in ESR2 were not significantly associated with prostate cancer risk, individually. The global test for the influence of any haplotype on the risk of prostate cancer was not significant (P = 0.31). However, we observed that men carrying two copies of one of the variant haplotypes (TACC) had a 1.46-fold increased risk of prostate cancer (99% confidence interval, 1.06-2.01) compared with men carrying zero copies of this variant haplotype. No SNPs or haplotypes were associated with advanced stage or high grade of prostate cancer. Conclusion: In our analysis focused on genetic variation common in Whites, we observed little evidence for any substantial association of inherited variation in ESR2 with risk of prostate cancer. A nominally significant (P < 0.01) association between the TACC haplotype and prostate cancer risk under the recessive model could be a chance finding and, in any event, would seem to contribute only slightly to the overall burden of prostate cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(10):1973–81)
- Published
- 2007
11. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer
- Author
-
Shamika Ketkar, Ross Lazarus, Edward Giovannucci, Peter Kraft, Yen-Ching Chen, and David J. Hunter
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Genotype ,CD14 ,Single-nucleotide polymorphism ,Lower risk ,Polymorphism, Single Nucleotide ,Prostate cancer ,Risk Factors ,Internal medicine ,medicine ,SNP ,Humans ,Protein Isoforms ,Genetic Predisposition to Disease ,Aged ,Neoplasm Staging ,business.industry ,Haplotype ,Homozygote ,Cancer ,Prostatic Neoplasms ,Odds ratio ,Middle Aged ,medicine.disease ,Toll-Like Receptor 4 ,Haplotypes ,Case-Control Studies ,Immunology ,business ,Follow-Up Studies - Abstract
Chronic inflammation has been hypothesized to be a risk factor for prostate cancer. The Toll-like receptor 4 (TLR4) presents the bacterial lipopolysaccharide (LPS), which interacts with ligand-binding protein and CD14 (LPS receptor) and activates expression of inflammatory genes through nuclear factor-κB and mitogen-activated protein kinase signaling. A previous case-control study found a modest association of a polymorphism in the TLR4 gene [11381G/C, GG versus GC/CC: odds ratio (OR), 1.26] with risk of prostate cancer. We assessed if sequence variants of TLR4 were associated with the risk of prostate cancer. In a nested case-control design within the Health Professionals Follow-up Study, we identified 700 participants with prostate cancer diagnosed after they had provided a blood specimen in 1993 and before January 2000. Controls were 700 age-matched men without prostate cancer who had had a prostate-specific antigen test after providing a blood specimen. We genotyped 16 common (>5%) single nucleotide polymorphisms (SNP) discovered in a resequencing study spanning TLR4 to test for association between sequence variation in TLR4 and prostate cancer. Homozygosity for the variant alleles of eight SNPs was associated with a statistically significantly lower risk of prostate cancer (TLR4_1893, TLR4_2032, TLR4_2437, TLR4_7764, TLR4_11912, TLR4_16649, TLR4_17050, and TLR4_17923), but the TLR4_15844 polymorphism corresponding to 11381G/C was not associated with prostate cancer (GG versus CG/CC: OR, 1.01; 95% confidence interval, 0.79-1.29). Six common haplotypes (cumulative frequency, 81%) were observed; the global test for association between haplotypes and prostate cancer was statistically significant (χ2 = 14.8 on 6 degrees of freedom; P = 0.02). Two common haplotypes were statistically significantly associated with altered risk of prostate cancer. Inherited polymorphisms of the innate immune gene TLR4 are associated with risk of prostate cancer. (Cancer Res 2005; 65(24): 11771-8)
- Published
- 2005
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.